eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2008
vol. 12
 
Share:
Share:
more
 
 
abstract:

The diagnosis of limited stage small-cell lung cancer

Beata Sas-Korczyńska
,
Ewa Wójcik
,
Elżbieta Łuczyńska
,
Jan Kulpa
,
Stanisław Korzeniowski

Współczesna Onkologia (2008) vol. 12; 1 (1–5)
Online publish date: 2008/03/20
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Small-cell lung cancer (SCLC) constitutes approximately 20% of all cases of lung cancer. The stage of disease is the most important prognostic factor. The aim of the study was the presentation of diagnostic examinations to identify patients with limited stage (LS) SCLC. The diagnostic procedures were performed in 87 patients with the primary diagnosis of SCLC between 2002 and 2005. The aim of these examinations was qualification of stage of SCLC. Diagnostic procedures included: radiological imaging, bone scan, and morphological and biochemical tests (Coulter blood count, and clinical biochemical liver and renal function tests), and serum levels of markers: lactic dehydrogenase (LDH), neuron-specific enolase (NSE) and pro-gastrin-releasing-peptide (ProGRP). Diagnostic procedures demonstrated the presence of distant metastases in 18 patients (20.69%) and they were classified as extensive stage (ES) SCLC. The most frequent localisation of metastases were: brain (7/18 patients), bones (5/18 patients) and liver (4/18 patients). LS SCLC was confirmed in 69 patients (79.31%). The diagnostic procedures performed before treatment showed: • enlargement of mediastinal lymph nodes in 43 patients (62.32%), • elevated serum levels of: NSE >24.7 ng/ml (in 39 pts. – 56.5%), ProGRP >50 pg/ml (in 54 pts. – 78.3%), and LDH >450 IU/ml (in 12 pts. – 17.4%). Patients with confirmed LS SCLC received concurrent chemo-radiotherapy. During the follow-up period 26 patients (37.7%) developed distant metastases. The most frequent localisation of metastases was: liver (9 pts.), brain (7 pts.), under diaphragmatic lymph nodes (7 pts.), and bones (6 pts.). There were not observed correlations between frequency of dissemination after treatment and elevated serum levels of markers before treatment.
keywords:

limited stage small-cell lung cancer, radiological imaging markers, NSE, ProGRP, LDH

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe